Literature DB >> 8660692

Active-site topologies of human CYP2D6 and its aspartate-301 --> glutamate, asparagine, and glycine mutants.

R Mackman1, R A Tschirret-Guth, G Smith, G P Hayhurst, S W Ellis, M S Lennard, G T Tucker, C R Wolf, P R Ortiz de Montellano.   

Abstract

Cytochrome P450 2D6 (CYP2D6) catalyzes the oxidation of substrates with a positively charged nitrogen atom 5-7 angstroms from the site of the oxidation. The active-site topology of CYP2D6 is examined here with phenyl-, 2-naphthyl-, and p-biphenyldiazene, which react with P450 enzymes to form sigma-bonded aryl-iron (Fe-Ar) complexes. Ferricyanide-mediated migration of the aryl group from the iron to the porphyrin nitrogens produces the N-arylprotoporphyrin IX regioisomers (NB:NA:NC:ND, in which the aryl group is bound to the nitrogen of pyrrole rings B, A, C, and D, respectively) in the following ratios (zero means <5%): phenyl, 10:90:00:00; 2-naphthyl, 09:91:00:00; and p-biphenyl, 16:84:00:00. These results suggest that the CYP2D6 active site is open above pyrrole ring A and to a small extent above pyrrole ring B but is closed above pyrrole rings C and D. This geometry differs from those determined by the same method for P450s for which crystal structures are available. Replacement of Asp-301 by a Glu, which preserves the carboxylate side chain, causes no detectable change in the N-aryl porphyrin regioisomer patterns and only minor changes in the catalytic activity. Replacement of Asp-301 by an Asn or Gly, which eliminates the negatively charged side chain, suppresses migration of the aryl groups to pyrrole ring B without impairing migration to pyrrole ring A and virtually abolishes catalytic activity. These results provide a refined model of the active site of CYP2D6. They confirm, furthermore, that the loss of activity observed when Asp-301 is replaced by a neutral residue is due to loss of the charge-pairing interaction with the substrate positive charge and/or subtle structural effects in the vicinity of pyrrole ring B, but not to major structural reorganization of the active site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660692     DOI: 10.1006/abbi.1996.0291

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4.

Authors:  F De Rienzo; F Fanelli; M C Menziani; P G De Benedetti
Journal:  J Comput Aided Mol Des       Date:  2000-01       Impact factor: 3.686

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

3.  Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.

Authors:  Jack U Flanagan; Lesley A McLaughlin; Mark J I Paine; Michael J Sutcliffe; Gordon C K Roberts; C Roland Wolf
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

4.  Ab initio molecular modeling in the study of drug metabolism.

Authors:  M D Segall; M C Payne; S W Ellis; G T Tucker; R N Boyes
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

5.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

7.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Authors:  Jack U Flanagan; Jean-Didier Maréchal; Richard Ward; Carol A Kemp; Lesley A McLaughlin; Michael J Sutcliffe; Gordon C K Roberts; Mark J I Paine; C Roland Wolf
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.